{"nctId":"NCT00085098","briefTitle":"Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor","startDateStruct":{"date":"2007-01"},"conditions":["Brain Tumor","Central Nervous System Tumor"],"count":24,"armGroups":[{"label":"Regimen A (radiotherapy only)","type":"EXPERIMENTAL","interventionNames":["Radiation: radiation therapy"]},{"label":"Regimen B (chemotherapy plus radiotherapy)","type":"EXPERIMENTAL","interventionNames":["Biological: filgrastim","Drug: carboplatin","Drug: cisplatin","Drug: cyclophosphamide","Drug: etoposide","Radiation: radiation therapy"]}],"interventions":[{"name":"filgrastim","otherNames":["Granulocyte Colony-Stimulating Factor","r-metHuG-CSF","G-CSF","Neupogen","NSC #61462"]},{"name":"carboplatin","otherNames":["Paraplatin","NSC #241240"]},{"name":"cisplatin","otherNames":["Cis-diamminedichloroplatinum II","Platinol-AQ","NSC #119875"]},{"name":"cyclophosphamide","otherNames":["Cytoxan","NSC #26271"]},{"name":"etoposide","otherNames":["VePesid","Etopophos","VP-16","NSC #141540"]},{"name":"radiation therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed primary CNS pure germ cell tumor\n\n  * Diagnosed within the past 31 days\n* Meets any 1 OR none (i.e., M0 \\[localized disease\\]) of the following staging criteria:\n\n  * M+ (disseminated disease)\n\n    * Leptomeningeal or intraventricular metastases visualized on MRI scans of the brain and spine\n    * Clumps of tumor cells on lumbar cerebrospinal fluid (CSF) cytology\n    * Visible tumor studding the walls of the lateral or third ventricles noted during endoscopy or surgery\n    * Primary tumor arising within the parenchyma of the brain, brainstem, or spinal cord\n    * Measurable multi-focal tumors arising in both the pineal and suprasellar regions (i.e., multiple midline tumors)\n    * Infiltrative, intra-axial extension on brain MRI \\> 1 cm beyond enhancing tumor\n  * Modified M+ (occult multi-focal disease)\n\n    * M0 at diagnosis with a localized pineal region tumor with signs and symptoms of diabetes insipidus without measurable disease in the suprasellar region\n* Lumbar CSF assay meeting criteria for the following marker profiles:\n\n  * Serum and CSF beta human chorionic gonadotropin (β-HCG) ≤ 50 IU/dL\n  * Serum alpha fetoprotein (AFP) ≤ 10 IU/L AND ≤ institutional norm\n  * CSF AFP ≤ 2.0 IU/L AND ≤ institutional norm\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 3 to 25\n\nPerformance status\n\n* Not specified\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Absolute neutrophil count \\> 1,000/mm\\^3\n* Platelet count \\> 100,000/mm\\^3 (transfusion independent)\n* Hemoglobin \\> 10.0 g/dL (transfusion allowed)\n\nHepatic\n\n* Bilirubin ≤ 1.5 times upper limit of normal (ULN)\n* aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\< 2.5 times ULN\n\nRenal\n\n* Creatinine adjusted according to age as follows\\*:\n\n  * No greater than 0.4 mg/dL (≤ 5 months)\n  * No greater than 0.5 mg/dL (6 months -11 months)\n  * No greater than 0.6 mg/dL (1 year-23 months)\n  * No greater than 0.8 mg/dL (2 years-5 years)\n  * No greater than 1.0 mg/dL (6 years-9 years)\n  * No greater than 1.2 mg/dL (10 years-12 years)\n  * No greater than 1.4 mg/dL (13 years and over \\[female\\])\n  * No greater than 1.5 mg/dL (13 years to 15 years \\[male\\])\n  * No greater than 1.7 mg/dL (16 years and over \\[male\\]) AND\n* Creatinine clearance OR radioisotope glomerular filtration rate \\> 70 mL/min\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Euthyroid (with or without levothyroxine sodium therapy) as determined by normal T4 ± thyroid-stimulating hormone levels\\*\n* Diabetes insipidus allowed provided patient is relatively stable on desmopressin acetate\n* Normal endogenous cortisol function\\*\n* Adequate antidiuretic hormone reserves\\* NOTE: \\*Unless receiving replacement therapy\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* Not specified\n\nEndocrine therapy\n\n* Concurrent replacement hormones allowed (e.g., corticosteroids, levothyroxine sodium, and desmopressin acetate)\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* Prior surgery for germ cell tumor allowed\n\nOther\n\n* No other prior therapy for germ cell tumor\n* Concurrent anticonvulsants allowed","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"25 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event-free Survival","description":"Data will be summarized as number of patients in the following categories at the time of data cutoff for analyses of 3-year EFS: 1)Experienced a qualifying event (QE) (see below);2)Event-free through 3 years of follow-up;3)Event-free until data cutoff (if less than 3 years of follow-up);4)Withdrew from study;5)Lost to follow-up.\n\nQEs: 1)disease progression, defined as increase \\>= 40% in tumor volume or \\>= 25% in tumor area of target lesions;2)development of new lesions;3)occurrence of a second malignant neoplasm, defined as a malignancy with different histological type from trial-qualifying diagnosis;4)death from any cause.\n\nStat. analyses will be based on time from enrollment to the earliest of: 1)occurrence of any of the QEs;2)withdrawal from study or lost to follow-up;3)completion of three years of follow-up event-free;4)data cutoff for completion of the statistical analyses for the protocol's primary objective.\n\nNOTE: Reported data are through May 2009 (see Caveats section).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Response to Regimen B","description":"To assess the complete response rate to pre-radiotherapy chemotherapy (Reg B only). Response was determined after completing 2-4 cycles of chemotherapy on Reg B. Complete Response (CR) is defined as disappearance of all target lesions.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Toxicity and Safety as Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0","description":"The analysis of toxicity will focus on estimating the rates of key acute and subacute toxicity occurring during the first induction chemotherapy. The list of toxicities of interest include Anemia or Febrile Neutropenia; Nausea or Vomiting; Infections and Infestations; Neutrophil or White blood count decrease; and Hypokalemia or Hyponatremia","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life (QOL) and Neurocognitive Assessment (NP)","description":"The primary endpoints for QOL and NP assessments will be the global scale value from each of these instruments at the two-year time point. Analyses of subscales (if they exist) and of assessments at other times will be of secondary interest. It is assumed that scale values are standardized to a reference normal population. The scores range from 0 to 100 with higher score reflecting better QoL or neurocognitive assessment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.60","spread":"17.95"},{"groupId":"OG001","value":"92.43","spread":"6.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.00","spread":"2.83"},{"groupId":"OG001","value":"42.50","spread":"5.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.00","spread":"2.83"},{"groupId":"OG001","value":"42.00","spread":"4.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.50","spread":"2.12"},{"groupId":"OG001","value":"60.50","spread":"3.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.04","spread":"6.15"},{"groupId":"OG001","value":"79.35","spread":"6.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.65","spread":"NA"},{"groupId":"OG001","value":"90.76","spread":"0.76"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":["Neutrophil count decreased","Lymphocyte count decreased","Platelet count decreased","White blood cell decreased","Hypokalemia"]}}}